Olfactomedin 4 (GW112, hGC-1) is an independent prognostic marker for survival in patients with colorectal cancer
Olfactomedin 4 (GW112, hGC-1) is an independent prognostic marker for survival in patients with colorectal cancer
复制标题
DOI：
10.3892/etm_00000013
复制
发表时间：
2010-01-01
影响因子：
2.7
通讯作者：
Yasui, Wataru
中科院分区：
文献类型：
--
作者：
Seko, Naotsugu;Oue, Naohide;Yasui, Wataru
结直肠癌（CRC）是世界范围内癌症相关死亡的主要原因之一，我们之前对四个原发性胃癌样本进行了基因表达序列分析（SAGE），并鉴定出了几个胃癌特异性基因，其中，olfactomedin 4 (OLFM4，也称为GW112或hGC-1) 1是癌症特异性表达的候选基因。我们通过免疫组化方法检测了olfactomedin 4在结直肠癌中的表达和分布。176例结直肠癌患者中，olfactomedin 4细胞质染色阳性59例（34%），olfactomedin 4阳性结直肠癌患者的T分型（P= 0.0180）、N分型（P= 0.0149）和分期（P= 0.0144）早于olfactomedin 4阴性结直肠癌患者。olfactomedin 4阳性CRC患者生存率高于olfactomedin 4阴性CRC患者（P= 0.0092）多因素分析显示，T分型、M分型和olfactomedin 4阴性表达是CRC患者生存率的独立预测因子。除olfactomedin 4细胞质染色外，侵袭前间质染色也有观察到。基质olfactomedin 4染色与任何临床病理特征或患者生存无关，这些结果表明olfactomedin 4是CRC患者长期生存的有价值的标志物
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide We previously performed Serial Analysis of Gene Expression (SAGE) on four primary gastric cancer samples and identified several gastric cancer-specific genes Of these genes, olfactomedin 4 (OLFM4, also known as GW112 or hGC-1) 1, a candidate gene for cancer-specific expression In the present study, we examined the expression and distribution of olfactomedin 4 in CRC by immunohistochemistry Of the 176 CRC cases, 59 (34%) were positive for cytoplasmic staining of olfactomedin 4 Olfactomedin 4-positive CRC cases showed earlier T classification (P=0 0180), N classification (P=0 0149) and stage (P=0 0144) than olfactomedin 4-negative CRC cases In the 176 CRC patients, those with olfactomedin 4-positive CRC had a better survival rate than patients with olfactomedin 4-negative CRC (P=0 0092) Multivariate analysis indicated that T classification, M classification and negative olfactomedin 4 expression were independent predictors of survival in patients with CRC In addition to cytoplasmic staining of olfactomedin 4, stromal staining at the invasive front was observed In total, 29 (16%) of the 176 CRC eases were positive for stromal olfactomedin 4, however, stromal olfactomedin 4 staining was not correlated with any clinicopathologic characteristic or with patient survival These results indicate that olfactomedin 4 is a valuable marker for long-term survival in patients with CRC